10x Genomics (TXG) Change in Account Payables (2018 - 2026)

10x Genomics has disclosed Change in Account Payables across 9 years of filings, most recently posting $4.8 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at $4.8 million, up 287.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.2 million (up 149.63% YoY), and the FY2025 annual result was -$2.1 million, up 36.61% from the prior year.
• Change in Account Payables came in at $4.8 million for Q1 2026 at 10x Genomics, up from -$5.4 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $7.4 million in Q2 2022 to a low of -$13.4 million in Q4 2024.
• The 5-year median for Change in Account Payables is -$196000.0 (2025), against an average of -$50411.8.
• Across the five-year window, Change in Account Payables surged 729.22% in 2022 and slumped 1331.25% in 2023, its largest moves.
• 10x Genomics' Change in Account Payables stood at -$224000.0 in 2022, then plunged by 1331.25% to -$3.2 million in 2023, then tumbled by 317.9% to -$13.4 million in 2024, then soared by 59.56% to -$5.4 million in 2025, then surged by 188.26% to $4.8 million in 2026.
• The last three Change in Account Payables figures came in at $4.8 million (Q1 2026), -$5.4 million (Q4 2025), and -$196000.0 (Q3 2025), per Business Quant data.